Cervical Cancer Screening: Pap, HPV, or Both — What to Offer and When to Stop

Clinical Practice Update — Screening Strategies by Age, Where Guidelines Agree and Differ, Managing the HPV-Positive Patient, and Special Populations

This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.

MDA-CCS-2026·14 min read

Clinical Focus

Age-appropriate cervical cancer screening with cytology (Pap), primary hrHPV testing, and cotesting; screening intervals; when to stop screening; management of discordant results; HPV vaccination and screening; special populations

Target Audience

Family physicians, general internists, obstetrician-gynecologists, nurse practitioners, physician assistants, midwives, residents

Setting

Outpatient primary care, women’s health clinics, community health centres

Source Evidence

•USPSTF Recommendation on Cervical Cancer Screening (2018)
•ACS Cervical Cancer Screening Guideline Update (2020)
•ACOG/ASCCP/SGO Practice Advisory on Updated Cervical Cancer Screening Guidelines (2021)
•ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Screening Tests (2019)

Key Clinical Takeaways

Cervical cancer screening guidelines showing age-based Pap smear HPV testing and cotesting recommendations for primary care clinicians — An age-based framework for cervical cancer screening in primary care.

1Nearly all cervical cancers are caused by persistent high-risk HPV infection — screening strategies are moving toward HPV-based testing as the primary approach → Context
2Ages 21–29: screen with cervical cytology (Pap) alone every 3 years — do not use HPV testing in this age group (USPSTF 2018 / ACOG 2021) → Ages 21–29
3Ages 30–65: three equally acceptable options — cytology every 3 years, primary hrHPV testing every 5 years, or cotesting every 5 years (USPSTF 2018) → Ages 30–65
4The ACS 2020 guideline goes further — it recommends starting at age 25 and prefers primary HPV testing every 5 years as the optimal strategy for all ages → Where Guidelines Differ
5Do not screen before age 21 — regardless of sexual history or HPV vaccination status → When Not to Screen
6Stop screening at age 65 if prior screening has been adequate and negative — defined as 3 consecutive negative cytology results or 2 consecutive negative HPV/cotest results within the past 10 years → When to Stop
7HPV vaccination does not change screening recommendations — vaccinated individuals should follow the same screening schedule → Vaccination
8The biggest barrier to cervical cancer prevention is underscreening, not the choice of screening test — any recommended strategy is better than none → Equity

What Should You Offer — and at What Age?

Cervical cancer screening has been one of the great success stories of preventive medicine, reducing cervical cancer incidence and mortality dramatically since the introduction of the Pap smear. The evidence now supports multiple effective strategies. The key clinical challenge is selecting the right strategy for the right patient at the right age.

Do not screen for cervical cancer before age 21, regardless of age of sexual debut or HPV vaccination status. Cervical cancer is extremely rare in this age group, and screening leads to unnecessary procedures that may cause harm (including anxiety, pain, and potential effects on future pregnancy outcomes from excisional treatment).

AgainstHigh EvidenceUSPSTF 2018 (D)ACOG 2021

Perform cervical cytology (Pap test) alone every 3 years for individuals aged 21–29 years. Do not use primary HPV testing in this age group per the USPSTF, because the high prevalence of transient HPV infection in younger individuals leads to elevated false-positive rates and unnecessary colposcopies without meaningful improvements in cancer detection.

Strong RecHigh EvidenceUSPSTF 2018 (A)ACOG 2021

Perform screening for individuals aged 30–65 years using any one of three strategies: cervical cytology alone every 3 years, primary hrHPV testing alone every 5 years, or cotesting (hrHPV plus cytology) every 5 years. All three strategies are equally recommended by the USPSTF. The choice should be guided by patient preference, local laboratory capabilities, and shared decision-making.

Strong RecHigh EvidenceUSPSTF 2018 (A)

Discontinue cervical cancer screening after age 65 in individuals who have had adequate prior negative screening and are not otherwise at high risk. Adequate prior screening is defined as 3 consecutive negative cytology results, or 2 consecutive negative cotesting or hrHPV results, within the past 10 years, with the most recent test within the recommended screening interval.

Strong RecHigh EvidenceUSPSTF 2018 (D)ACS 2020

Do not screen individuals who have had a hysterectomy with removal of the cervix and who have no history of CIN2 or higher-grade lesion or cervical cancer. This applies regardless of age.

AgainstHigh EvidenceUSPSTF 2018 (D)

Clinical Pearl: These recommendations apply to asymptomatic, average-risk individuals with a cervix. They do NOT apply to patients with a history of high-grade precancerous lesions (CIN2+), cervical cancer, in utero DES exposure, or immunocompromise (including HIV). These patients require more intensive, individualised surveillance per ASCCP guidelines.

How Do the Screening Strategies Compare?

Strategy	Interval	What It Detects	Key Advantage	Key Limitation
Cytology alone (Pap)	Every 3 years	Abnormal cervical cells	Lowest false-positive rate; widely available; decades of established infrastructure	Lower sensitivity than HPV-based strategies; requires more frequent screening; subject to sampling and interpretation variability
Primary hrHPV testing	Every 5 years	High-risk HPV infection	Highest sensitivity for CIN3+; longer screening interval; strong negative predictive value (a negative test provides greater reassurance than a negative Pap)	Higher false-positive rate than cytology alone; detects transient HPV infections that may never cause disease; FDA-approved primary HPV tests have limited availability in some settings
Cotesting (HPV + Pap)	Every 5 years	Both abnormal cells and HPV infection	Marginally higher sensitivity than either test alone; familiar to clinicians; widely used in US practice	Highest false-positive rate of the three strategies; requires two tests with minimal gain over HPV alone; adds cost and patient burden

Primary HPV testing must use an FDA-approved stand-alone test. As of 2026, three tests hold this approval: cobas HPV (Roche), BD Onclarity HPV, and Aptima HPV (Hologic). Not all HPV tests are approved for primary screening.
The ACS 2020 guideline recommends primary HPV testing as the PREFERRED strategy, with cotesting and cytology alone as transitional alternatives until HPV testing is universally available.

Clinical Decision Pathway

Cervical Cancer Screening: 4 Questions

Question 1: Does this patient have a cervix?

No (total hysterectomy without history of CIN2+ or cervical cancer) → no screening needed. Yes → proceed.

Question 2: How old is the patient?

Under 21 → do not screen. Ages 21–29 → Pap every 3 years. Ages 30–65 → choose one: Pap every 3 years, hrHPV every 5 years, or cotesting every 5 years. Over 65 with adequate prior screening → stop screening.

Question 3: Is the patient at high risk?

History of CIN2+, cervical cancer, DES exposure, or immunosuppression (especially HIV) → these patients require individualised, more frequent surveillance per ASCCP 2019 risk-based management guidelines. Standard recommendations do not apply.

Question 4: What if the result is abnormal?

Follow ASCCP 2019 risk-based management guidelines. Key principle: management is determined by the patient’s risk of CIN3+ based on current and past test results, not by a single test alone. Low-risk results may warrant surveillance; high-risk results warrant colposcopy. Use the ASCCP management app or risk tables to guide decisions.

Evidence in Context

Where USPSTF, ACS, and ACOG Agree

All three bodies agree that cervical cancer screening saves lives, that all three screening strategies (cytology, HPV testing, cotesting) are effective, that screening should stop after age 65 with adequate prior negative results, that individuals who have had a hysterectomy (with cervix removal and no history of CIN2+) do not need screening, and that HPV vaccination does not change screening recommendations.

Where USPSTF, ACS, and ACOG Differ

Starting age: USPSTF 2018 and ACOG 2021 recommend starting at age 21. ACS 2020 recommends starting at age 25, citing low cervical cancer incidence in the 21–24 age group, the availability of HPV vaccination, and the harms of treating transient lesions.

Preferred strategy: USPSTF 2018 treats cytology, HPV testing, and cotesting as equally acceptable for ages 30–65. ACS 2020 explicitly prefers primary HPV testing every 5 years, calling cytology and cotesting “transitional” options to be phased out.

HPV testing for ages 25–29: USPSTF 2018 recommends cytology only for 21–29. ACS 2020 recommends primary HPV for all ages 25+. ACOG/ASCCP/SGO note that primary HPV testing is FDA-approved from age 25 and can be considered for 25–29.

In practice: ACOG emphasises that the specific strategy matters less than consistent adherence to any recommended schedule, and that health equity concerns (including underscreening in vulnerable populations) should guide implementation decisions.

HPV Vaccination and Screening

HPV vaccination has led to dramatic reductions in HPV prevalence and cervical precancerous lesions in vaccinated populations. However, no guideline body currently recommends different screening for vaccinated individuals. This is because vaccination coverage remains below target levels nationally, the US lacks a vaccine registry to confirm individual vaccination history, and HPV vaccines do not cover all oncogenic HPV types. As vaccinated cohorts age into screening populations, future guidelines will likely incorporate vaccination status — but for now, the screening schedule is the same for all.

The 2024 USPSTF Draft Update: What May Change

In December 2024, the USPSTF released a draft update to the cervical cancer screening recommendation. Key proposed changes include: designating primary hrHPV testing every 5 years as the preferred strategy for ages 30–65 (with cytology and cotesting as alternatives rather than equals), and adding HPV self-collection as an acceptable option. The draft maintains cytology every 3 years for ages 21–29 and continues to start screening at age 21. This draft is NOT yet finalised and may change based on public comment. Until finalised, the 2018 recommendation remains in effect.

What We Still Don’t Know

How vaccination will reshape screening: As more vaccinated individuals reach screening age, the prevalence of oncogenic HPV will decline, potentially reducing the yield of screening and raising questions about extending intervals or raising starting ages further.

Self-collected HPV sampling: Evidence is growing that self-collected vaginal HPV samples perform similarly to clinician-collected cervical samples. Self-collection could dramatically improve access for underscreened populations but is not yet standard in the US (though included in the 2024 USPSTF draft).

Optimal screening for immunocompromised patients: Current guidelines recommend more frequent screening for HIV-positive individuals, but evidence-based intervals for other forms of immunosuppression (transplant recipients, autoimmune disease) are less well defined.

References

1.Curry SJ, Krist AH, Owens DK, et al. Screening for Cervical Cancer: USPSTF Recommendation Statement. JAMA. 2018;320(7):674–686. doi:10.1001/jama.2018.10897
2.Fontham ETH, Wolf AMD, Church TR, et al. Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update From the ACS. CA Cancer J Clin. 2020;70(5):321–346. doi:10.3322/caac.21628
3.ACOG, ASCCP, SGO. Updated Cervical Cancer Screening Guidelines. Practice Advisory. April 2021. acog.org
4.Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102–131. doi:10.1097/LGT.0000000000000525

How to Read the Evidence Tags

Every recommendation carries two tags. These are Medaptly’s simplified interpretations.

Recommendation Strength

Tag	Meaning	In Practice
Strong Rec	Benefits clearly outweigh risks.	Standard practice.
Moderate Rec	Evidence favours benefit; some uncertainty.	Most patients; individualise.
Conditional Rec	Depends on individual factors.	Shared decision-making.
Against	No benefit or potential harm.	Avoid.

Evidence Quality

Tag	Meaning	Confidence
High Evidence	Multiple RCTs or meta-analyses.	Very confident.
Moderate Evidence	Single RCT or large observational studies.	Reasonably confident.
Low Evidence	Expert consensus or small studies.	Less certain.

These are Medaptly’s simplified interpretations. For full classification systems, consult the original documents in References.

Article Information

For Educational Purposes Only. This is original clinical education content informed by current published guidelines and clinical evidence. It does not constitute medical advice, is not endorsed by any guideline body (USPSTF, ACS, ACOG, ASCCP, or any other organisation), and does not replace individualised clinical judgement or institutional protocols. Readers are encouraged to consult the original source guidelines listed in the References section for the full evidence review and complete recommendation sets. Abnormal screening results should be managed per ASCCP 2019 risk-based management consensus guidelines.